Sage Therapeutics (NASDAQ:SAGE) Lowered to Sell at StockNews.com

StockNews.com cut shares of Sage Therapeutics (NASDAQ:SAGE) from a hold rating to a sell rating in a research report released on Friday morning.

A number of other research analysts have also recently weighed in on SAGE. JPMorgan Chase & Co. boosted their price objective on shares of Sage Therapeutics from $24.00 to $29.00 and gave the company an overweight rating in a research report on Tuesday, March 26th. Scotiabank cut their price objective on shares of Sage Therapeutics from $34.00 to $19.00 and set a sector outperform rating for the company in a report on Thursday, April 18th. Wedbush reissued a neutral rating and set a $24.00 price objective on shares of Sage Therapeutics in a research report on Wednesday, April 17th. Oppenheimer lowered their target price on shares of Sage Therapeutics from $25.00 to $17.00 and set a market perform rating on the stock in a report on Thursday, April 18th. Finally, Royal Bank of Canada lifted their target price on shares of Sage Therapeutics from $21.00 to $26.00 and gave the stock a sector perform rating in a research report on Thursday, February 15th. Two equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of Hold and a consensus target price of $39.28.

Sage Therapeutics Stock Performance

Shares of SAGE stock opened at $12.89 on Friday. Sage Therapeutics has a 52-week low of $10.92 and a 52-week high of $59.99. The company has a 50-day simple moving average of $19.64 and a two-hundred day simple moving average of $20.88. The company has a market capitalization of $774.82 million, a price-to-earnings ratio of -1.42 and a beta of 0.86.

Sage Therapeutics (NASDAQ:SAGE) last released its earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($0.55) EPS for the quarter, beating the consensus estimate of ($1.28) by $0.73. The company had revenue of $77.97 million for the quarter, compared to analyst estimates of $60.15 million. Sage Therapeutics had a negative net margin of 626.32% and a negative return on equity of 54.41%. The firm’s quarterly revenue was up 2621.5% compared to the same quarter last year. During the same quarter last year, the firm earned ($2.47) EPS. On average, sell-side analysts forecast that Sage Therapeutics will post -6.3 EPS for the current fiscal year.

Institutional Trading of Sage Therapeutics

Hedge funds have recently made changes to their positions in the stock. CWM LLC raised its position in Sage Therapeutics by 274.2% during the third quarter. CWM LLC now owns 1,205 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 883 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its position in Sage Therapeutics by 95.5% during the third quarter. China Universal Asset Management Co. Ltd. now owns 1,531 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 748 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Sage Therapeutics by 17.4% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,289 shares of the biopharmaceutical company’s stock valued at $191,000 after acquiring an additional 1,375 shares in the last quarter. Values First Advisors Inc. bought a new position in Sage Therapeutics during the third quarter valued at approximately $219,000. Finally, Quest Partners LLC bought a new position in Sage Therapeutics during the fourth quarter valued at approximately $261,000. 99.22% of the stock is owned by hedge funds and other institutional investors.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.